Molecular Partners AG (OTCMKTS:MLLCF – Get Free Report)’s stock price traded down 9.4% on Monday . The company traded as low as $4.53 and last traded at $4.53. 300 shares were traded during trading, a decline of 28% from the average session volume of 415 shares. The stock had previously closed at $5.00.
Molecular Partners Stock Performance
The stock’s 50-day moving average is $5.62 and its two-hundred day moving average is $5.80.
About Molecular Partners
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.
Recommended Stories
- Five stocks we like better than Molecular Partners
- The 3 Best Fintech Stocks to Buy Now
- Abacus Life’s CEO on Cracking the Code of Longevity Returns
- The Basics of Support and Resistance
- Elon Musk and Trump Push for Self-Driving Cars: 3 Stocks to Gain
- How to Invest in Small Cap Stocks
- Discover the 3 Best Performing Stocks That Went Public in 2024
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
